Cogent Biosciences (COGT) Consolidated Net Income (2017 - 2026)

Cogent Biosciences (COGT) has reported Consolidated Net Income for 10 consecutive years, with -$111.2 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Consolidated Net Income fell 54.48% year-over-year to -$111.2 million; the TTM figure through Mar 2026 stood at -$382.5 million (down 41.15% YoY), while the FY2025 annual figure was -$1.1 billion, down 126.83% from the prior year.
• Consolidated Net Income slipped to -$111.2 million in Q1 2026 per COGT's latest filing, from -$110.1 million in the prior quarter.
• Across five years, Consolidated Net Income topped out at -$35.9 million in Q1 2022 and bottomed at -$111.2 million in Q1 2026.
• Historically, Consolidated Net Income has averaged -$66.1 million across 5 years, with a median of -$62.8 million in 2024.
• Annual changes were most pronounced in 2022 — Consolidated Net Income sank 243.33% — and 2023, when it soared 36.61%.
• Cogent Biosciences' Consolidated Net Income stood at -$40.0 million in 2022, then slumped by 47.54% to -$59.0 million in 2023, then fell by 1.64% to -$60.0 million in 2024, then sank by 83.56% to -$110.1 million in 2025, then fell by 1.04% to -$111.2 million in 2026.
• Business Quant data shows COGT's Consolidated Net Income at -$111.2 million in Q1 2026, -$110.1 million in Q4 2025, and -$85.2 million in Q3 2025.